Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.25.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Costs and expenses:      
Cost of sales $ (254)    
Research and development (10,458) $ (39,992) $ (17,617)
General and administrative (7,984) (7,476) (12,766)
Total operating expenses (18,696) (47,468) (30,383)
Operating loss (18,696) (47,468) (30,383)
Interest expense, net (2,522) (1,428) (2,361)
Adjustments to fair value of derivatives (3,269) 11,056 5,458
Cancellation of share options     (17,350)
Other (expense) / income, net (47) 82 503
Total other (expense) / income (5,838) 9,710 (13,750)
Loss before income taxes (24,534) (37,758) (44,133)
Income tax expense (240) (613) (301)
Net loss $ (24,774) $ (38,371) $ (44,434)
Net loss per share - basic $ (1.26) $ (2.96) $ (3.63)
Net loss per share - diluted $ (1.26) $ (2.96) $ (3.63)
Weighted average ordinary shares outstanding - basic 19,699,260 12,962,362 12,236,607
Weighted average ordinary shares outstanding - diluted 19,699,260 12,962,362 12,236,607
Statements of Comprehensive Loss      
Net loss $ (24,774) $ (38,371) $ (44,434)
Unrealized (loss) / income on marketable securities (1) 351 (350)
Comprehensive loss $ (24,775) $ (38,020) $ (44,784)